ARTICLE | Clinical News
GTI-2501: Began Phase I testing
March 26, 2001 8:00 AM UTC
Lorus Therapeutics Inc. (TSE:LOR; LORFF), Toronto, Ontario Product: GTI-2501 Business: Cancer Therapeutic category: Antisense, Cell proliferation Target: Ribonucleotide reductase Description: Antisen...